January 22, 2015 | Check-Cap, the Israeli medical device company that has invented non-invasive imaging tests for colon cancer, announced a revision of its original IPO prospectus. The company has reportedly revised their prospectus with the US Securities & Exchange Commission to state the company hopes to raise between $12-$14.4 million at a share price ranging between $10-12 per share. The new prospectus would give Check-Cap a company valuation of $83-99 million after money. After the company goes public, it will be traded on NASDAQ under the ticker symbol CHEK. Check-Cap was founded in 2005 by CTO Dr. Yoav Kimchy.